
Evolutions in Hepatocellular Carcinoma in the Era of COVID-19
This OncLive webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on patients with HCC.
- How the pandemic has impacted the diagnosis of patients with HCC
- Current approaches to surgery, transplant and radiotherapy for patients with HCC
- Considerations for treatment strategies in HCC in the era of COVID-19
Kevin Kim, MD
Faculty:
Kevin Kim, MD
Professor of Radiology and Biomedical Imaging
Professor of Medicine (Medical Oncology)
Section Chief, Interventional Radiology
Reena J. Salgia, MD
Reena J. Salgia, MD
Medical Director, Liver Cancer Clinic
Program Director, Gastroenterology/Transplant Hepatology Fellowship
Senior Staff Physician, Hepatology
Henry Ford Hospital
Michael Morse, MD, MHS, FACP
Michael Morse, MD, MHS, FACP
Professor of Medicine
Professor in the Department of Surgery
Gastrointestinal Oncology
Duke University Health System
Richard S. Finn, MD
Richard S. Finn, MD
Professor of Clinical Medicine
Department of Medicine, Division of Hematology/Oncology
Geffen School of Medicine, University of California, Los Angeles (UCLA)
Director of the Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Sponsored by: Genentech



































